Citation Impact
Citing Papers
SuFEx-enabled, agnostic discovery of covalent inhibitors of human neutrophil elastase
2019 StandoutNobel
Pharmacological inhibition of cystine–glutamate exchange induces endoplasmic reticulum stress and ferroptosis
2014 Standout
The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype
2001 Standout
The MRP gene encodes an ATP-dependent export pump for leukotriene C4 and structurally related conjugates.
1994
Cell Growth Inhibition by Antitumor Prostaglandin and its Modulation by MRP/GS-X Pump
1997 StandoutNobel
Phase I and pharmacokinetic study of paclitaxel in combination with biricodar, a novel agent that reverses multidrug resistance conferred by overexpression of both MDR1 and MRP.
1998
The human multidrug resistance protein MRP1 translocates sphingolipid analogs across the plasma membrane
1999
Multidrug resistance in cancer: role of ATP–dependent transporters
2002 Standout
In situ click chemistry generation of cyclooxygenase-2 inhibitors
2017 Standout
The Corticosteroid Receptor Hypothesis of Depression
2000 Standout
Reversal of multidrug resistance by co-delivery of tariquidar (XR9576) and paclitaxel using long-circulating liposomes
2011
The Blood–Brain Barrier
2015 Standout
Cyclosporins as drug resistance modifiers
1992
Complete in vivo reversal of P‐glycoprotein pump function in the blood‐brain barrier visualized with positron emission tomography
1998
Pharmacological characterization of LY335979: A potent cyclopropyldibenzosuberane modulator of P-glycoprotein
1997
Conjugate export pumps of the multidrug resistance protein (MRP) family: localization, substrate specificity, and MRP2-mediated drug resistance
1999
Phase I trial of doxorubicin with cyclosporine as a modulator of multidrug resistance.
1994
Multidrug resistance (MDR) in cancer
2000
Absence of the mdr1a P-Glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A.
1995
Drug penetration in solid tumours
2006 Standout
Microemulsion-based media as novel drug delivery systems
2000 Standout
Principles of nanoparticle design for overcoming biological barriers to drug delivery
2015 Standout
Phase I study of mitoxantrone plus etoposide with multidrug blockade by SDZ PSC-833 in relapsed or refractory acute myelogenous leukemia.
1997
Cancer drug resistance: an evolving paradigm
2013 Standout
Growth inhibition, cytokinesis failure and apoptosis of multidrug-resistant leukemia cells after treatment with P-glycoprotein inhibitory agents
1999
Hyaluronan: from extracellular glue to pericellular cue
2004 Standout
Identification and Characterization of the Binding Sites of P-Glycoprotein for Multidrug Resistance-Related Drugs and Modulators
2004
Cremophor EL
2001 Standout
Nanoparticles in cancer therapy and diagnosis
2002 Standout
P-Glycoprotein Limits Oral Availability, Brain, and Fetal Penetration of Saquinavir Even with High Doses of Ritonavir
2001
Principles of bioactive lipid signalling: lessons from sphingolipids
2008 Standout
The influence of expression of P-glycoprotein on the penetration of anticancer drugs through multicellular layers
2000
Combined treatment of Bcl‐2 antisense oligodeoxynucleotides (G3139), p‐glycoprotein inhibitor (PSC833), and sterically stabilized liposomal doxorubicin suppresses growth of drug‐resistant growth of drug‐resistant breast cancer in severely combined immunodeficient mice
2003
Multidrug resistance and the role of P-glycoprotein knockout mice
1995
Availability of PSC833, a substrate and inhibitor of P-glycoproteins, in various concentrations of serum
1998
Experimental reversal of P-glycoprotein-mediated multidrug resistance by pharmacological chemosensitisers
1996
Chemoprevention of Colon Cancer by Organoselenium Compounds and Impact of High- or Low-Fat Diets
1997
Phase II study of tariquidar, a selective P‐glycoprotein inhibitor, in patients with chemotherapy‐resistant, advanced breast carcinoma
2005
Differential inhibition by cyclosporins of primary‐active ATP‐dependent transporters in the hepatocyte canalicular membrane
1993
The molecular interaction of the high affinity reversal agent XR9576 with P‐glycoprotein
1999
SuFExable polymers with helical structures derived from thionyl tetrafluoride
2021 StandoutNobel
Targeting multidrug resistance in cancer
2006 Standout
Click Chemistry in Proteomic Investigations
2020
Echinocandin antifungal drugs
2003 Standout
ABC transporters as multidrug resistance mechanisms and the development of chemosensitizers for their reversal.
2005
Effect of Multidrug Resistance-Reversing Agents on Transporting Activity of Human Canalicular Multispecific Organic Anion Transporter
1999
Comparison of cyclosporin A, verapamil, PSC-833 and cremophor EL as enhancing agents of VP-16 in murine lymphoid leukemias
1995
Inhibition of cell-mediated cytolysis and P-glycoprotein function in natural killer cells by verapamil isomers and cyclosporine a analogs
1995
From MDR to MXR: new understanding of multidrug resistance systems, their properties and clinical significance
2001
Polyaromatic alkaloids from marine invertebrates as cytotoxic compounds and inhibitors of multidrug resistance caused by P-glycoprotein
1996
Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview
2003 Standout
P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs.
1996
Microtubules as a target for anticancer drugs
2004 Standout
HMG‐CoA reductase inhibitors and P‐glycoprotein modulation
2001
Pharmacokinetic and Pharmacodynamic Implications of P‐glycoprotein Modulation
2001
A Pragmatic Guide to Enrichment Strategies for Mass Spectrometry–Based Glycoproteomics
2020 StandoutNobel
Optimizing the Absorption of Valspodar, a P‐glycoprotein Modulator, Part I: Selecting an Oral Formulation and Exploring its Clinical Pharmacokinetics/Dynamics
1997
Liposomal drug delivery systems: From concept to clinical applications
2012 Standout
Sulfonyl Fluoride Analogues as Activity‐Based Probes for Serine Proteases
2012
The Glut athione S-Transferase Supergene Family: Regulation of GST and the Contribution of the lsoenzymes to Cancer Chemoprotection and Drug Resistance Part I
1995 Standout
Multidrug-resistant Human Sarcoma Cells with a Mutant P-Glycoprotein, Altered Phenotype, and Resistance to Cyclosporins
1997
Sulfur(VI) Fluoride Exchange (SuFEx): Another Good Reaction for Click Chemistry
2014 StandoutNobel
Modulation and prevention of multidrug resistance by inhibitors of P-glycoprotein
1997
Drug Resistance and the Solid Tumor Microenvironment
2007 Standout
Click Chemistry for Drug Development and Diverse Chemical–Biology Applications
2013 Standout
Mitoxantrone, Etoposide, and Cytarabine With or Without Valspodar in Patients With Relapsed or Refractory Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome: A Phase III Trial (E2995)
2004
SuFEx Click Chemistry Enabled Late-Stage Drug Functionalization
2018 StandoutNobel
Biochemical Modulation of Cisplatin Mechanisms of Action: Enhancement of Antitumor Activity and Circumvention of Drug Resistance
2003 Standout
Azidopine noncompetitively interacts with vinblastine and cyclosporin A binding to P-glycoprotein in multidrug resistant cells.
1991
Phase I Study of Paclitaxel in Combination With a Multidrug Resistance Modulator, PSC 833 (Valspodar), in Refractory Malignancies
2000
Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview
2012 Standout
Tumour stem cells and drug resistance
2005 Standout
Parallel Phase I Studies of Daunorubicin Given With Cytarabine and Etoposide With or Without the Multidrug Resistance Modulator PSC-833 in Previously Untreated Patients 60 Years of Age or Older With Acute Myeloid Leukemia: Results of Cancer and Leukemia Group B Study 9420
1999
In vitro and in vivo reversal of multidrug resistance by GF120918, an acridonecarboxamide derivative.
1993
Anti-cancer-prostaglandin-induced cell-cycle arrest and its modulation by an inhibitor of the ATP-dependent glutathione S-conjugate export pump (GS-X pump)
1998 StandoutNobel
Multidimensional SuFEx Click Chemistry: Sequential Sulfur(VI) Fluoride Exchange Connections of Diverse Modules Launched From An SOF4 Hub
2017 StandoutNobel
Phase 3 study of the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age and older with acute myeloid leukemia: Cancer and Leukemia Group B Study 9720
2002
Molecular Properties That Influence the Oral Bioavailability of Drug Candidates
2002 Standout
BIOCHEMICAL, CELLULAR, AND PHARMACOLOGICAL ASPECTS OF THE MULTIDRUG TRANSPORTER
1999 Standout
Update 1 of: Macrolactonizations in the Total Synthesis of Natural Products
2012
Treatment of Refractory and Relapsed Acute Myelogenous Leukemia With Combination Chemotherapy Plus the Multidrug Resistance Modulator PSC 833 (Valspodar)
1999
Cooperative capture synthesis: yet another playground for copper-free click chemistry
2016 StandoutNobel
Treatment of Refractory and Relapsed Acute Myelogenous Leukemia With Combination Chemotherapy Plus the Multidrug Resistance Modulator PSC 833 (Valspodar)
1999
Flow cytometric assay of modulation of P-glycoprotein function in whole blood by the multidrug resistance inhibitor GG918.
1996
The Hitchhiker’s Guide to Flow Chemistry
2017 Standout
MRP2, a human conjugate export pump, is present and transports fluo 3 into apical vacuoles of Hep G2 cells
2000
Phase I trial of XR9576 in healthy volunteers demonstrates modulation of P-glycoprotein in CD56+ lymphocytes after oral and intravenous administration.
2000
Clinical Studies with Modulators of Multidrug Resistance
1995
Multicellular resistance: a paradigm for clinical resistance?
2000
Mitsunobu and Related Reactions: Advances and Applications
2009
Phosphine Organocatalysis
2018 Standout
Mechanisms of resistance to anticancer drugs: the role of the polymorphic ABC transporters ABCB1 and ABCG2
2005
Combination of quinine as a potential reversing agent with mitoxantrone and cytarabine for the treatment of acute leukemias: a randomized multicenter study
1996
Mechanisms of Cancer Drug Resistance
2002 Standout
A fluorogenic screening platform enables directed evolution of an alkyne biosynthetic tool
2016 StandoutNobel
In vitro and in vivo reversal of P-glycoprotein-mediated multidrug resistance by a novel potent modulator, XR9576.
2001
The multidrug resistance modulator valspodar (PSC 833) is metabolized by human cytochrome P450 3A. Implications for drug-drug interactions and pharmacological activity of the main metabolite.
1998
Enhanced oral bioavailability of paclitaxel in mice treated with the P-glycoprotein blocker SDZ PSC 833
1997
Cyclosporin A Is a Broad-Spectrum Multidrug Resistance Modulator
2005
Synergistic Antifungal Activities of Bafilomycin A 1 , Fluconazole, and the Pneumocandin MK-0991/Caspofungin Acetate (L-743,873) with Calcineurin Inhibitors FK506 and L-685,818 against Cryptococcus neoformans
2000
Brain Corticosteroid Receptor Balance in Health and Disease*
1998 Standout
Phase I/II Study of the P-Glycoprotein Modulator PSC 833 in Patients With Acute Myeloid Leukemia
2001
Diversity Oriented Clicking (DOC): Divergent Synthesis of SuFExable Pharmacophores from 2‐Substituted‐Alkynyl‐1‐Sulfonyl Fluoride (SASF) Hubs
2020 StandoutNobel
Fluorosulfuryl Isocyanate Enabled SuFEx Ligation of Alcohols and Amines
2021 StandoutNobel
Discovery and characterization of OC144-093, a novel inhibitor of P-glycoprotein-mediated multidrug resistance.
2000
An architectonic macrolide library based on a C2-symmetric macrodiolide toward pharmaceutical compositions
2015 StandoutNobel
Phase II Study of Paclitaxel and Valspodar (PSC 833) in Refractory Ovarian Carcinoma: A Gynecologic Oncology Group Study
2001
A phase I trial of doxorubicin, paclitaxel, and valspodar (PSC 833), a modulator of multidrug resistance.
2001
Arylfluorosulfates Inactivate Intracellular Lipid Binding Protein(s) through Chemoselective SuFEx Reaction with a Binding Site Tyr Residue
2016 StandoutNobel
P-Glycoprotein Inhibitor Valspodar (PSC 833) Increases the Intracellular Concentrations of Daunorubicin In Vivo in Patients With P-Glycoprotein–Positive Acute Myeloid Leukemia
2000
Lamellarins and Related Pyrrole-Derived Alkaloids from Marine Organisms
2007 Standout
Synthesis and biological activity of pyrrole, pyrroline and pyrrolidine derivatives with two aryl groups on adjacent positions
2006 Standout
A Phase I Trial of a Potent P-Glycoprotein Inhibitor, Zosuquidar Trihydrochloride (LY335979), Administered Intravenously in Combination with Doxorubicin in Patients with Advanced Malignancy
2004
Organoselenium and Organotellurium Compounds: Toxicology and Pharmacology
2004 Standout
“Inverse Drug Discovery” Strategy To Identify Proteins That Are Targeted by Latent Electrophiles As Exemplified by Aryl Fluorosulfates
2017 StandoutNobel
Works of D Boesch being referenced
In-cell Selectivity Profiling of Serine Protease Inhibitors by Activity-based Proteomics
2008
Reversion of the P-glycoprotein-mediated multidrug resistance of cancer cells by FK-506 derivatives
1993
Extent and persistence of P-glycoprotein inhibition in multidrug-resistant P388 cells after exposure to resistance-modifying agents
1994
Derivatives of a Novel Cyclopeptolide. 2. Synthesis, Activity against Multidrug Resistance in CHO and KB Cells in vitro, and Structure-Activity Relationships
1994
Restoration of daunomycin retention in multidrug-resistant P388 cells by submicromolar concentrations of SDZ PSC 833, a nonimmunosuppressive cyclosporin derivative
1991
Overcoming multidrug resistance in Chinese hamster ovary cells in vitro by cyclosporin A (Sandimmune) and non-immunosuppressive derivatives
1989
SDZ 280-446, a novel semi-synthetic cyclopeptolide: in vitro and in vivo circumvention of the P-glycoprotein-mediated tumour cell multidrug resistance
1992
In vivo circumvention of P-glycoprotein-mediated multidrug resistance of tumor cells with SDZ PSC 833.
1991